Correction: ENDOLUNG trial. A phase 1/2 study of the Akt/mTOR inhibitor and autophagy inducer Ibrilatazar (ABTL0812) in combination with paclitaxel/carboplatin in patients with advanced/recurrent endometrial cancer (BMC Cancer, (2024), 24, 1, (876), 10.1186/s12885-024-12501-5)

Alexandra Leary; Purificación Estévez-García; Renaud Sabatier; Isabelle Ray-Coquard; Margarita Romeo; Pilar Barretina-Ginesta; Marta Gil-Martin; Elena Garralda; Joaquim Bosch-Barrera; Teresa Morán; Paloma Martin-Martorell; Ernest Nadal; Pere Gascón; Jordi Rodon; Jose M. Lizcano; Pau Muñoz-Guardiola; Gemma Fierro-Durán; Oriol Pedrós-Gámez; Héctor Pérez-Montoyo; Marc Yeste-Velasco; Marc Cortal; Antonio Pérez-Campos; Jose Alfon; Carles Domenech; Alejandro Pérez-Fidalgo; Ana Oaknin

doi:10.1186/s12885-024-12700-0

Correction: ENDOLUNG trial. A phase 1/2 study of the Akt/mTOR inhibitor and autophagy inducer Ibrilatazar (ABTL0812) in combination with paclitaxel/carboplatin in patients with advanced/recurrent endometrial cancer (BMC Cancer, (2024), 24, 1, (876), 10.1186/s12885-024-12501-5)

Alexandra Leary, Purificación Estévez-García, Renaud Sabatier, Isabelle Ray-Coquard, Margarita Romeo, Pilar Barretina-Ginesta, Marta Gil-Martin, Elena Garralda, Joaquim Bosch-Barrera, Teresa Morán, Paloma Martin-Martorell, Ernest Nadal, Pere Gascón, Jordi Rodon, Jose M. Lizcano, Pau Muñoz-Guardiola, Gemma Fierro-Durán, Oriol Pedrós-Gámez, Héctor Pérez-Montoyo, Marc Yeste-VelascoMarc Cortal, Antonio Pérez-Campos, Jose Alfon, Carles Domenech, Alejandro Pérez-Fidalgo, Ana Oaknin

Résultats de recherche: Contribution à un journal › !!Comment/debate

Résumé

Following publication of the original article [1], the authors reported the the equal contribution statement was missing in the original submission. The correct equal contribution statement is: Alejandro Pérez-Fidalgo and Ana Oaknin contributed equally to this work.

langue originale	Anglais
Numéro d'article	911
journal	BMC Cancer
Volume	24
Numéro de publication	1
Les DOIs	https://doi.org/10.1186/s12885-024-12700-0
état	Publié - 1 déc. 2024

Accès au document

10.1186/s12885-024-12700-0

Autres fichiers et liens

Lien vers la publication dans Scopus

Contient cette citation

Leary, A., Estévez-García, P., Sabatier, R., Ray-Coquard, I., Romeo, M., Barretina-Ginesta, P., Gil-Martin, M., Garralda, E., Bosch-Barrera, J., Morán, T., Martin-Martorell, P., Nadal, E., Gascón, P., Rodon, J., Lizcano, J. M., Muñoz-Guardiola, P., Fierro-Durán, G., Pedrós-Gámez, O., Pérez-Montoyo, H., ... Oaknin, A. (2024). Correction: ENDOLUNG trial. A phase 1/2 study of the Akt/mTOR inhibitor and autophagy inducer Ibrilatazar (ABTL0812) in combination with paclitaxel/carboplatin in patients with advanced/recurrent endometrial cancer (BMC Cancer, (2024), 24, 1, (876), 10.1186/s12885-024-12501-5). BMC Cancer, 24(1), Article 911. https://doi.org/10.1186/s12885-024-12700-0

Leary, Alexandra ; Estévez-García, Purificación ; Sabatier, Renaud et al. / Correction : ENDOLUNG trial. A phase 1/2 study of the Akt/mTOR inhibitor and autophagy inducer Ibrilatazar (ABTL0812) in combination with paclitaxel/carboplatin in patients with advanced/recurrent endometrial cancer (BMC Cancer, (2024), 24, 1, (876), 10.1186/s12885-024-12501-5). Dans: BMC Cancer. 2024 ; Vol 24, Numéro 1.

@article{519f16f197994817bad6da2bea264106,

title = "Correction: ENDOLUNG trial. A phase 1/2 study of the Akt/mTOR inhibitor and autophagy inducer Ibrilatazar (ABTL0812) in combination with paclitaxel/carboplatin in patients with advanced/recurrent endometrial cancer (BMC Cancer, (2024), 24, 1, (876), 10.1186/s12885-024-12501-5)",

abstract = "Following publication of the original article [1], the authors reported the the equal contribution statement was missing in the original submission. The correct equal contribution statement is: Alejandro P{\'e}rez-Fidalgo and Ana Oaknin contributed equally to this work.",

author = "Alexandra Leary and Purificaci{\'o}n Est{\'e}vez-Garc{\'i}a and Renaud Sabatier and Isabelle Ray-Coquard and Margarita Romeo and Pilar Barretina-Ginesta and Marta Gil-Martin and Elena Garralda and Joaquim Bosch-Barrera and Teresa Mor{\'a}n and Paloma Martin-Martorell and Ernest Nadal and Pere Gasc{\'o}n and Jordi Rodon and Lizcano, {Jose M.} and Pau Mu{\~n}oz-Guardiola and Gemma Fierro-Dur{\'a}n and Oriol Pedr{\'o}s-G{\'a}mez and H{\'e}ctor P{\'e}rez-Montoyo and Marc Yeste-Velasco and Marc Cortal and Antonio P{\'e}rez-Campos and Jose Alfon and Carles Domenech and Alejandro P{\'e}rez-Fidalgo and Ana Oaknin",

note = "Publisher Copyright: {\textcopyright} The Author(s) 2024.",

year = "2024",

month = dec,

day = "1",

doi = "10.1186/s12885-024-12700-0",

language = "English",

volume = "24",

journal = "BMC Cancer",

issn = "1471-2407",

number = "1",

}

Leary, A, Estévez-García, P, Sabatier, R, Ray-Coquard, I, Romeo, M, Barretina-Ginesta, P, Gil-Martin, M, Garralda, E, Bosch-Barrera, J, Morán, T, Martin-Martorell, P, Nadal, E, Gascón, P, Rodon, J, Lizcano, JM, Muñoz-Guardiola, P, Fierro-Durán, G, Pedrós-Gámez, O, Pérez-Montoyo, H, Yeste-Velasco, M, Cortal, M, Pérez-Campos, A, Alfon, J, Domenech, C, Pérez-Fidalgo, A & Oaknin, A 2024, 'Correction: ENDOLUNG trial. A phase 1/2 study of the Akt/mTOR inhibitor and autophagy inducer Ibrilatazar (ABTL0812) in combination with paclitaxel/carboplatin in patients with advanced/recurrent endometrial cancer (BMC Cancer, (2024), 24, 1, (876), 10.1186/s12885-024-12501-5)', BMC Cancer, VOL. 24, Numéro 1, 911. https://doi.org/10.1186/s12885-024-12700-0

Correction: ENDOLUNG trial. A phase 1/2 study of the Akt/mTOR inhibitor and autophagy inducer Ibrilatazar (ABTL0812) in combination with paclitaxel/carboplatin in patients with advanced/recurrent endometrial cancer (BMC Cancer, (2024), 24, 1, (876), 10.1186/s12885-024-12501-5). / Leary, Alexandra; Estévez-García, Purificación; Sabatier, Renaud et al.
Dans: BMC Cancer, Vol 24, Numéro 1, 911, 01.12.2024.

Résultats de recherche: Contribution à un journal › !!Comment/debate

TY - JOUR

T1 - Correction

T2 - ENDOLUNG trial. A phase 1/2 study of the Akt/mTOR inhibitor and autophagy inducer Ibrilatazar (ABTL0812) in combination with paclitaxel/carboplatin in patients with advanced/recurrent endometrial cancer (BMC Cancer, (2024), 24, 1, (876), 10.1186/s12885-024-12501-5)

AU - Leary, Alexandra

AU - Estévez-García, Purificación

AU - Sabatier, Renaud

AU - Ray-Coquard, Isabelle

AU - Romeo, Margarita

AU - Barretina-Ginesta, Pilar

AU - Gil-Martin, Marta

AU - Garralda, Elena

AU - Bosch-Barrera, Joaquim

AU - Morán, Teresa

AU - Martin-Martorell, Paloma

AU - Nadal, Ernest

AU - Gascón, Pere

AU - Rodon, Jordi

AU - Lizcano, Jose M.

AU - Muñoz-Guardiola, Pau

AU - Fierro-Durán, Gemma

AU - Pedrós-Gámez, Oriol

AU - Pérez-Montoyo, Héctor

AU - Yeste-Velasco, Marc

AU - Cortal, Marc

AU - Pérez-Campos, Antonio

AU - Alfon, Jose

AU - Domenech, Carles

AU - Pérez-Fidalgo, Alejandro

AU - Oaknin, Ana

PY - 2024/12/1

Y1 - 2024/12/1

N2 - Following publication of the original article [1], the authors reported the the equal contribution statement was missing in the original submission. The correct equal contribution statement is: Alejandro Pérez-Fidalgo and Ana Oaknin contributed equally to this work.

AB - Following publication of the original article [1], the authors reported the the equal contribution statement was missing in the original submission. The correct equal contribution statement is: Alejandro Pérez-Fidalgo and Ana Oaknin contributed equally to this work.

UR - http://www.scopus.com/inward/record.url?scp=85199967810&partnerID=8YFLogxK

U2 - 10.1186/s12885-024-12700-0

DO - 10.1186/s12885-024-12700-0

M3 - Comment/debate

AN - SCOPUS:85199967810

SN - 1471-2407

VL - 24

JO - BMC Cancer

JF - BMC Cancer

IS - 1

M1 - 911

ER -

Leary A, Estévez-García P, Sabatier R, Ray-Coquard I, Romeo M, Barretina-Ginesta P et al. Correction: ENDOLUNG trial. A phase 1/2 study of the Akt/mTOR inhibitor and autophagy inducer Ibrilatazar (ABTL0812) in combination with paclitaxel/carboplatin in patients with advanced/recurrent endometrial cancer (BMC Cancer, (2024), 24, 1, (876), 10.1186/s12885-024-12501-5). BMC Cancer. 2024 déc. 1;24(1):911. doi: 10.1186/s12885-024-12700-0